<DOC>
	<DOCNO>NCT01425853</DOCNO>
	<brief_summary>The purpose study determine whether combination Chondroitin sulfate ( CS ) Glucosamine Hydrochloride ( GH ) similar efficacy Celecoxib ( CE ) treatment patient moderate severe knee osteoarthritis ( OA ) .</brief_summary>
	<brief_title>Study Efficacy Safety Chondroitin Sulfate + Glucosamine Hydrochloride Versus Celecoxib Knee Osteoarthritis</brief_title>
	<detailed_description>The primary objective study show combination treatment CS/GH comparable efficacy CE pain reduction baseline 6 month treatment measure Western Ontario McMaster Universities Arthritis Index ( WOMAC ) pain subscale knee OA patient moderate severe pain .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<criteria>At least 40 year age Primary OA knee accord American College Rheumatology ( ACR ) criteria OA radiological stage II III accord Kellgren Lawrence Patients moderatesevere knee pain Subjects active malignancy type history malignancy within last five year Concurrent arthritic disease ( antecedent and/or current sign ) could confound interfere evaluation pain efficacy chondrocalcinosis , Paget 's disease ipsilateral limb target knee , rheumatoid arthritis , aseptic osteonecrosis , gout , septic arthritis , ochronosis , acromegaly , haemochromatosis , Wilson 's disease , osteochondromatosis seronegative spondyloarthropathy , mixed connective tissue disease , collagen vascular disease , psoriasis , inflammatory bowel disease Pain part body great knee pain could interfere evaluation index joint Patients fibromyalgia Subjects history heart attack stroke , experience chest pain related heart disease , serious disease heart Subjects high risk cardiovascular ( CV ) event Subjects active acute chronic infection require antimicrobial therapy , serious viral ( e.g. , hepatitis , herpes zoster , HIV positivity ) fungal infection Subjects history recurrent Upper Gastrointestinal ( UGI ) ulceration active inflammatory bowel disease ( e.g. , Crohn 's disease ulcerative colitis ) , significant coagulation defect Subjects diagnose treated oesophageal , gastric , pyloric channel , duodenal ulceration within 30 day prior receive first dose study medication Washout period OA treatment begin study .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>